CD8A and neoplasm: In murine studies, such as Russo et al., 2024, combination therapy with decitabine and PeptiCRAd resulted in notable spatial reorganization of intratumoral CD8+ T cells, shifting from perivascular zones to deeper tumor regions, an effect associated with enhanced immune surveillance [59].